Sorafenib in Treating Patients With Malignant Mesothelioma
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | April 5, 2005 | ||||
Last Updated Date | March 22, 2011 | ||||
Start Date ICMJE | October 2004 | ||||
Primary Completion Date | June 2007 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Response rate (complete and partial response) [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures ICMJE |
Response rate (complete and partial response) | ||||
Change History | Complete list of historical versions of study NCT00107432 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE | |||||
Original Secondary Outcome Measures ICMJE | |||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Sorafenib in Treating Patients With Malignant Mesothelioma | ||||
Official Title ICMJE | A Phase II Study of BAY 43-9006 (NSC #724772, IND #69896) in Patients With Malignant Mesothelioma | ||||
Brief Summary | RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. |
||||
Detailed Description | OBJECTIVES: Primary
Secondary
OUTLINE: This is a multicenter study. Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at least every 2 months for 1 year, every 4 months for 1 year, and then every 6 months for 1 year. PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study within 6-8 months. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 2 | ||||
Study Design ICMJE | Masking: Open Label Primary Purpose: Treatment |
||||
Condition ICMJE | Malignant Mesothelioma | ||||
Intervention ICMJE | Drug: sorafenib tosylate | ||||
Study Arm (s) | |||||
Publications * | Janne PA, Wang XF, Krug LM, et al.: Sorafenib in malignant mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307). [Abstract] J Clin Oncol 25 (Suppl 18): A-7707, 435s, 2007. | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Active, not recruiting | ||||
Enrollment ICMJE | 51 | ||||
Estimated Completion Date | January 2014 | ||||
Primary Completion Date | June 2007 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
|
||||
Gender | Both | ||||
Ages | 18 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00107432 | ||||
Other Study ID Numbers ICMJE | CDR0000415372, U10CA031946, CALGB-30307 | ||||
Has Data Monitoring Committee | No | ||||
Responsible Party | Monica M Bertagnolli, MD, Cancer and Leukemia Group B | ||||
Study Sponsor ICMJE | Cancer and Leukemia Group B | ||||
Collaborators ICMJE | National Cancer Institute (NCI) | ||||
Investigators ICMJE |
|
||||
Information Provided By | Cancer and Leukemia Group B | ||||
Verification Date | March 2011 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |